A randomised phase II trial to evaluate the efficacy of DPX-Survivac (EMD 640744) in patients with advanced ovarian cancer

Trial Profile

A randomised phase II trial to evaluate the efficacy of DPX-Survivac (EMD 640744) in patients with advanced ovarian cancer

Planning
Phase of Trial: Phase II

Latest Information Update: 20 Mar 2015

At a glance

  • Drugs EMD 640744 (Primary)
  • Indications Ovarian cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Mar 2015 The design of this large randomised trial is being finalised and it is expected to be initiated in 2015, according to an Immunovaccine media release.
    • 07 Jul 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top